Who we are
Paul Janssen Futurelab Leiden is an initiative of Leiden University Medical Center to create International blended learning program for tomorrow’s leaders in Biomedical science. We offer professional learning programs with a unique blend of online education and on-campus training to improve the processes for discovery and development of new medical interventions.
Our approach to professional learning
Treating diseases has become increasingly complex. A multidisciplinary approach – from science to business – is becoming increasingly important to address these challenges . We offer inspiring blended courses to help guide the next generation of leaders in life sciences through the layered skill set that they will need to make their own. Our mantra is learning by doing and our courses stimulate active participation with a wide variety of teaching methods, such as animations, expert interviews, self-assessment tools, polls and , teaching cases. and (online) discussions.
We aim to provide 3 key professional learning experiences:
- Interdisciplinary team work with real-world case studies
- Inspiring ‘What Really Happened’ sessions with experts from the field
- Sharing expertise with colleagues and key players from industry, academia, and authority
What’s in a name
Dr. Paul Janssen (1926 - 2003), founder of Janssen Pharmaceutical, was a pioneer in the field of biomedical research, as well as a highly successful entrepreneur. With a drive and curiosity that led him to pursue biomedical research, medicine, chemistry, pharmacology, and entrepreneurship, he discovered, developed, and brought to market many new medicinal products which significantly impacted the lives of many patients. At Paul Janssen Futurelab Leiden, Dr. Janssen’s multidisciplinary approach serves as a role model to inspire future generations of entrepreneurial researchers.
On January 30, 2016, Paul Janssen Futurelab Leiden signed an agreement with Baroness Dora Janssen-Arts to use the name for this initiative. We are, and will remain, an independent non-profit organization and have no financial ties with companies. We do collaborate closely with pharmaceutical and life sciences companies, with authorities and other academic institutions, for instance, for the development of teaching cases that are used in the courses and scholarships that are awarded to promising candidates who would otherwise not be able to join the courses.
Our alumni
Our alumni are more than 150 professionals from over 10 countries in Africa, Asia, Europe, Middle East and USA who are working on the development of new medical interventions from industry, in academia, industry, at authorities etc have already participated in our courses. The on-campus has created a lasting experience and a solid network among our alumni and contributors. Will you be part of the Future?
Our contributors
We are fortunate to have many excellent contributors who help to make the on-campus course a success. Below are a few contributors who have shared their expertise with our participants in guest lectures and discussions during the 2017 course. Visit the contributor's page to see all contributors.
A selection of our contributors
Juliane Bernholz
Chief Operating Officer
AM Pharma
Onno van de Stolpe
CEO
Galapagos B.V.
Marc Martens
Head of Bird & Bird's Regulatory, Public & Administrative Law group in Brussels
Bird & Bird
Aliki Nichogiannopoulou
Director
European Patent Office
Ton van der Hoven
CEO
SurgVision BV
Bruno Vandermeulen
IP Lawyer - Member of the Brussels Bar
Independent IP practitioner
On-campus
Nacer Lounis
Senior Principal Scientist
Janssen Pharmaceutica
On-campus
Tine de Marez
Senior Director, Compound Development Team Leader TB
Johnson & Johnson
Bert Leufkens
Professor of Pharmaceutical Policy and Regulatory Science and Former Chair of Medicines Evaluation Board
Utrecht Institute for Pharmaceutical Sciences (UIPS)
Henk Schuring
VP-Head Rare Nephrology
Sanofi Genzyme
Sjaak Bot
VP, Head of EMEA Regulatory Affairs
Janssen
Bernd van der Meulen
Professor of Comparative Food Law
European Institute for Food Law / Renmin University of China Law School
Frank Landolt
Chief Counsel Legal & Intellectual Property
Confo Therapeutics
On-campus
Erik Niks
Neurologist - Pediatric neurologist
Leiden University Medical Center
On-campus
Piet Hinoul
Global Head, Pre-Clinical, Clinical and Medical Affairs
J&J Ethicon
On-campus
Ad Sitsen
Owner
ClinPharMed Consultancy for Drug Development
Eline Bunnik
Assistant professor Medical Ethics and Philosophy of Medicine
Erasmus MC
Maurits Westerik
IE/IT lawyer
Coupry
Bart Swinkels
Partner
NLO
Karin Verzijden
Food and Pharma Lawyer
Axon Lawyers
On-campus
Ineke Jonker-Hoogerkamp
Consultant Regulatory Affairs and Drug Development
Paul Janssen Futurelab & Eagle Pharma Consult
Kees Recourt
Investment Manager
Mibiton Foundation
Paul Stoffels
Chief scientific officer
Johnson & Johnson
Tom Huizinga
Head of the Department of Rheumatology
Leiden University Medical Centre
On-campus
Marcel Kenter
Director
Paul Janssen Futurelab Leiden
On-campus
Koen Andries
VP Scientific Fellow Infectious Diseases Discovery
Janssen Pharmaceutica NV
On-campus
Andreas Wallnöfer
General Partner
BioMed Partners Venture Capital (former Head of Clinical Research & Exploratory Development at F. Hoffmann-La Roche Ltd.)
On-campus
Justin Hay
Pharmacokinetics Assessor
Medicines and Healthcare products Regulatory Agency
On-campus
André Elferink
Clinical epidemiologist
Dutch Medicines Evaluation Board
On-campus
Rob Zuiker
Senior Clinical Scientist
CHDR
Hans-Georg Eichler
Senior Medical Officer
European Medicines Agency
On-campus
Robert Klautz
Thoracic Surgeon
Leiden University Medical Centre
On-campus
Matthijs Moerland
Research Director Translational Biomarkers
CHDR
Joris Rotmans, MD, PhD
internist-nephrologist
LUMC
On-campus
Janneke Meulenberg
CEO
Arthrogen
Inge de Lepeleire
Director Translational Pharmacology
MSD Europe
On-campus
Koos Burggraaf
Research Director CVS & Metabolism
CHDR
Johan Garssen
Director Immunology Platform
Danone/Nutricia Research
On-campus
Ingrid de Visser
Senior Clinical Scientist
CHDR
Rick Kuntz
Senior Vice President and Chief Scientific, Clinical and Regulatory Officer
Medtronic
On-campus
Geert Jan Groeneveld
Research Director CNS
CHDR
Oliver Bisazza
Director Regulatory Policy
Medtronic
Saco de Visser
Teacher and Clinical Pharmacologist
Paul Janssen Futurelab Leiden
On-campus
Adam Cohen
CEO and clinical pharmacologist
Centre for Human Drug Research
Richard Shull
Head of Deal Structuring and Trading Fundamentals
Shell
Pierre Peeters
Former site head early stage development
Organon
Our team
Marcel Kenter
Director
Ineke Jonker
Teacher
Saco de Visser
Teacher Clinical Development
Bruno vanderMeulen
Teacher Intellectual Property
Kees Recourt
Developer Intellectual Property course
Building towards an advanced master
Behind the scenes we are developing new courses and are building towards an advanced master program. The advanced master revolves around the main theme: Improving the discovery and development of new medical interventions and will incorporate topics in biomedical science, clinical development, leadership and entrepreneurship. A blended course can be done as a stand-alone course or blended courses from several topics can be combined to will earn a recognized master degree. Each blended course is a part-time module consisting of a multi-week online course (with an average work load of 5 hours per week) and an 1 or 2 on-campus courses. The blended courses are designed for graduated biomedical post-academic professionals with working experience in academia, industry or at authorities. Combine professional learning with your career and personal life thanks to the part-time character of the blended courses and take the next step in your career.
Articles from our blog
This may be interesting for you
Dora Janssen launches Paul Janssen Futurelab Leiden
Baroness Dora Janssen-Arts — widow of Dr. Paul Janssen — officially announced the launch of Paul Janssen Futurelab Leiden, an international training program providing blended learning (online and on-campus) to biomedical professionals with an entrepreneurial spirit. This new training program is an initiative of the Leiden University Medical Center in collaboration with the Center for Human Drug Research and Leiden University, sponsored by grants from ZonMw and Health~Holland. Listen to Baroness Dora Janssen's message for the next generation of scientists.